These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 14500340)
1. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340 [TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Liu MY; Poellinger L; Walker CL Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690 [TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Kwiatkowski DJ; Manning BD Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323 [TBL] [Abstract][Full Text] [Related]
5. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells. Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687 [TBL] [Abstract][Full Text] [Related]
6. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Kenerson HL; Aicher LD; True LD; Yeung RS Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518 [TBL] [Abstract][Full Text] [Related]
7. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. Nobukini T; Thomas G Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827 [TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919 [TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809 [TBL] [Abstract][Full Text] [Related]
10. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. El-Hashemite N; Walker V; Kwiatkowski DJ Cancer Res; 2005 Mar; 65(6):2474-81. PubMed ID: 15781664 [TBL] [Abstract][Full Text] [Related]
12. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Lee DF; Kuo HP; Chen CT; Hsu JM; Chou CK; Wei Y; Sun HL; Li LY; Ping B; Huang WC; He X; Hung JY; Lai CC; Ding Q; Su JL; Yang JY; Sahin AA; Hortobagyi GN; Tsai FJ; Tsai CH; Hung MC Cell; 2007 Aug; 130(3):440-55. PubMed ID: 17693255 [TBL] [Abstract][Full Text] [Related]
13. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway. Jiang X; Yeung RS Cancer Res; 2006 May; 66(10):5258-69. PubMed ID: 16707451 [TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin. Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. Nellist M; Burgers PC; van den Ouweland AM; Halley DJ; Luider TM Biochem Biophys Res Commun; 2005 Aug; 333(3):818-26. PubMed ID: 15963462 [TBL] [Abstract][Full Text] [Related]
16. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Kobayashi T; Minowa O; Sugitani Y; Takai S; Mitani H; Kobayashi E; Noda T; Hino O Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8762-7. PubMed ID: 11438694 [TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Astrinidis A; Henske EP Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294 [TBL] [Abstract][Full Text] [Related]
18. Missense mutations to the TSC1 gene cause tuberous sclerosis complex. Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of mTOR in tuberous sclerosis. Sampson JR Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643 [TBL] [Abstract][Full Text] [Related]
20. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations. Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M; Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]